Cargando…

Associations and prognostic significance of diffuse myocardial fibrosis by cardiovascular magnetic resonance in heart failure with preserved ejection fraction

BACKGROUND: Increased myocardial fibrosis may play a key role in heart failure with preserved ejection fraction (HFpEF) pathophysiology. The study aim was to evaluate the presence, associations, and prognostic significance of diffuse fibrosis in HFpEF patients compared to age- and sex-matched contro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roy, Clotilde, Slimani, Alisson, de Meester, Christophe, Amzulescu, Mihaela, Pasquet, Agnes, Vancraeynest, David, Beauloye, Christophe, Vanoverschelde, Jean-Louis, Gerber, Bernhard L., Pouleur, Anne-Catherine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081897/ https://www.ncbi.nlm.nih.gov/pubmed/30086783 http://dx.doi.org/10.1186/s12968-018-0477-4

Ejemplares similares

Diabetic phenotype and prognosis of patients with heart failure and preserved ejection fraction in a real life cohort
por: Lejeune, Sibille, et al.
Publicado: (2021)

Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction
por: Roy, Clotilde, et al.
Publicado: (2020)

Age and sex corrected normal reference values of T1, T2 T2* and ECV in healthy subjects at 3T CMR
por: Roy, Clotilde, et al.
Publicado: (2017)

Impact of left ventricular outflow tract ellipticity on the grading of aortic stenosis in patients with normal ejection fraction
por: Maes, Frédéric, et al.
Publicado: (2017)

Histological Validation of measurement of diffuse interstitial myocardial fibrosis by myocardial extravascular volume fraction from Modified Look-Locker imaging (MOLLI) T1 mapping at 3 T
por: de Meester de Ravenstein, Christophe, et al.
Publicado: (2015)

Diagnostic and Prognostic Accuracy of Aortic Valve Calcium Scoring in Patients With Moderate-to-Severe Aortic Stenosis
por: Boulif, Jamila, et al.
Publicado: (2021)

Myocardial strain imaging: review of general principles, validation, and sources of discrepancies
por: Amzulescu, M S, et al.
Publicado: (2019)

Can viability assessment by DE-MRI predict survival in patients with multivessel disease and low ejection fraction? Influence of treatment strategies
por: Gerber, Bernhard L, et al.
Publicado: (2011)

Evaluation of myocardial fibrosis with cardiac magnetic resonance contrast-enhanced t1 mapping in adults patients with aortic stenosis
por: Nastase, Oana A, et al.
Publicado: (2015)

Iron overload in polytransfused patients without heart failure is associated with subclinical alterations of systolic left ventricular function using cardiovascular magnetic resonance tagging
por: Seldrum, Stéphanie, et al.
Publicado: (2011)

α(V)β(3) integrin-targeted microSPECT/CT imaging of inflamed atherosclerotic plaques in mice
por: Vancraeynest, David, et al.
Publicado: (2016)

Combined coronary and late-enhanced multidetector-computed tomography for delineation of the etiology of left ventricular dysfunction: comparison with coronary angiography and contrast-enhanced cardiac magnetic resonance imaging
por: le Polain de Waroux, Jean-Benoît, et al.
Publicado: (2008)

Multivendor comparison of global and regional 2D cardiovascular magnetic resonance feature tracking strains vs tissue tagging at 3T
por: Militaru, Sebastian, et al.
Publicado: (2021)

Diffuse right ventricular fibrosis in heart failure with preserved ejection fraction and pulmonary hypertension
por: Patel, Ravi B., et al.
Publicado: (2020)

3D histopathology of stenotic aortic valve cusps using ex vivo microfocus computed tomography
por: Pestiaux, Camille, et al.
Publicado: (2023)

Quantification of primary mitral regurgitation by echocardiography: A practical appraisal
por: Altes, Alexandre, et al.
Publicado: (2023)

Diffuse myocardial fibrosis by post-contrast T1-time predicts outcome in heart failure with preserved ejection fraction
por: Marzluf, Beatrice A, et al.
Publicado: (2013)

Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
por: Sweeney, Mark, et al.
Publicado: (2020)

Effects of Kangdaxin on myocardial fibrosis in heart failure with preserved ejection fraction rats
por: Wu, Xiang, et al.
Publicado: (2022)

The clinical impact of valvular heart disease in a population-based cohort of subjects aged 80 and older
por: Rezzoug, Nawel, et al.
Publicado: (2016)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Heart failure with preserved ejection fraction
por: Rigolli, Marzia, et al.
Publicado: (2013)

Heart failure with preserved ejection fraction
por: ElGuindy, Ahmed, et al.
Publicado: (2012)

Assessment of left ventricular mass and volumes by three-dimensional echocardiography in patients with or without wall motion abnormalities: comparison against cine magnetic resonance imaging
por: Pouleur, A-C, et al.
Publicado: (2008)

Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction
por: Yoshihisa, Akiomi, et al.
Publicado: (2017)

Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview
por: Michalska-Kasiczak, Marta, et al.
Publicado: (2018)

Left ventricular fibrosis and hypertrophy are associated with mortality in heart failure with preserved ejection fraction
por: Garg, Pankaj, et al.
Publicado: (2021)

Liver fibrosis scores and atrial fibrillation incidence in heart failure with preserved ejection fraction
por: Liu, Xiao, et al.
Publicado: (2022)

AMP-activated protein kinase preserves endothelial tight junctions in the coronary microcirculation during sepsis
por: Castanares-Zapatero, D, et al.
Publicado: (2012)

Characteristics and Prognosis of Patients With Moderate Aortic Stenosis and Preserved Left Ventricular Ejection Fraction
por: Delesalle, Geraud, et al.
Publicado: (2019)

Biomarkers in heart failure with preserved ejection fraction
por: Meijers, W. C., et al.
Publicado: (2016)

Management of heart failure with preserved ejection fraction
por: Gard, Emma, et al.
Publicado: (2020)

Managing heart failure with preserved ejection fraction
por: Davidson, Alexander, et al.
Publicado: (2020)

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Comorbidities in heart failure with preserved ejection fraction
por: Deichl, Andrea, et al.
Publicado: (2022)

Interleukin-16 Promotes Cardiac Fibrosis and Myocardial Stiffening in Heart Failure with Preserved Ejection Fraction
por: Tamaki, Shunsuke, et al.
Publicado: (2013)

Microvascular dysfunction and cardiac fibrosis in heart failure with preserved ejection fraction: a case report
por: Narang, Nikhil, et al.
Publicado: (2017)

Predictors of myocardial fibrosis and response to anti-fibrotic therapy in heart failure with preserved ejection fraction
por: Lewis, Gavin A., et al.
Publicado: (2022)

Comparison of liver fibrosis scores for predicting mortality and morbidity in heart failure with preserved ejection fraction
por: Cao, Yalin, et al.
Publicado: (2023)

CA125, Galectin-3 and FGF-23 are interrelated in heart failure with reduced ejection fraction
por: Gruson, Damien, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d5fht2u58ap80lkj193jte5fiu